Skip to main content
. 2013 Jul-Aug;6(6):307–316.

Figure 1. Study Design.

Figure 1

aData availability for data set 1 (Truven Health Analytics MarketScan) ended in Q1 of 2011.

bData availability for data set 2 (Optum Insight Clinformatics Data Mart) ended in Q2 of 2012.

ADT indicates androgen-deprivation therapy; CRPC, castration-resistant prostate cancer; Q, quarter.